<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017368</url>
  </required_header>
  <id_info>
    <org_study_id>ANBL00P1</org_study_id>
    <secondary_id>COG-ANBL00P1</secondary_id>
    <secondary_id>CDR0000068681</secondary_id>
    <nct_id>NCT00017368</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma</brief_title>
  <official_title>A Pilot Study Of Tandem High Dose Chemotherapy With Stem Cell Rescue Following Induction Therapy In Children With High Risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. Peripheral&#xD;
      stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by&#xD;
      peripheral stem cell transplantation in treating children who have newly diagnosed&#xD;
      neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity and feasibility of high-dose thiotepa and cyclophosphamide with&#xD;
           autologous peripheral blood stem cell (PBSC) transplantation and sargramostim (GM-CSF)&#xD;
           followed by high-dose carboplatin, etoposide, and melphalan with second PBSC&#xD;
           transplantation, GM-CSF, and isotretinoin after induction in children with newly&#xD;
           diagnosed high-risk neuroblastoma.&#xD;
&#xD;
        -  Determine the role of the meta-iodobenzylguanidine (MIBG) scan in assessing response to&#xD;
           tandem transplantation and minimal residual disease therapy in these patients.&#xD;
&#xD;
        -  Determine the feasibility of quantitative polymerase chain reaction for&#xD;
           neuroblastoma-specific ribonucleic acids at specific stages of treatment as a prognostic&#xD;
           indicator of outcome in these patients.&#xD;
&#xD;
        -  Determine the immune recovery by quantitation of lymphocyte subsets in these patients&#xD;
           and limited functional analysis after completion of this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to peripheral blood&#xD;
      stem cell (PBSC) selection (selected PBSCs vs unselected PBSCs). (Selected PBSC stratum&#xD;
      closed to accrual as of 7/17/02.)&#xD;
&#xD;
        -  Induction/harvest:&#xD;
&#xD;
             -  Course 1: Patients receive etoposide (VP-16) IV over 1 hour on days 2-4, cisplatin&#xD;
                IV over 6 hours (beginning after VP-16 infusion) on days 1-5, and filgrastim&#xD;
                (G-CSF) subcutaneously (SC) beginning on day 6 and continuing until blood counts&#xD;
                recover.&#xD;
&#xD;
             -  Course 2: Patients receive vincristine IV and doxorubicin IV over 15 minutes on day&#xD;
                1, cyclophosphamide IV over 6 hours on days 1 and 2, and sargramostim (GM-CSF) SC&#xD;
                beginning on day 3 and continuing until PBSC are harvested. Beginning after&#xD;
                completion of course 2 and when blood counts recover, autologous PBSC are&#xD;
                harvested.&#xD;
&#xD;
             -  Course 3: Patients receive VP-16 IV over 1 hour and ifosfamide IV over 1 hour on&#xD;
                days 1-5 and G-CSF SC beginning on day 6 and continuing until blood counts recover.&#xD;
&#xD;
             -  Course 4: Patients receive VP-16 IV over 1 hour on days 1-3, carboplatin IV over 2&#xD;
                hours (beginning after VP-16 infusion) on days 1 and 2, and G-CSF SC beginning on&#xD;
                day 4 and continuing until blood counts recover.&#xD;
&#xD;
             -  Course 5: Patients receive treatment as in course 2 but supported by G-CSF. Courses&#xD;
                1-5 each last 3-4 weeks. Patients undergo resection of the primary tumor after&#xD;
                course 4 or 5 unless primary resection was completed at diagnosis (which is not&#xD;
                recommended), no primary site is found, or the primary site is unresectable.&#xD;
                Patients complete courses 1-5 and then proceed to the first conditioning/PBSC&#xD;
                transplantation (PBSCT) in the absence of disease progression or unacceptable&#xD;
                toxicity.&#xD;
&#xD;
        -  First conditioning/PBSCT: Patients receive high-dose thiotepa IV on days -7 to -5 and&#xD;
           cyclophosphamide IV over 1 hour on days -5 to -2. CD34+ PBSC are reinfused on day 0.&#xD;
           GM-CSF is administered SC beginning on day 5 and continuing until blood counts recover.&#xD;
           If blood counts have not recovered by day 28, unselected PBSC are reinfused. In the&#xD;
           absence of disease progression or unacceptable toxicity, patients proceed to the second&#xD;
           conditioning/PBSCT.&#xD;
&#xD;
        -  Second conditioning/PBSCT: Beginning within 6-8 weeks after initiating the first&#xD;
           conditioning, patients receive high-dose carboplatin IV continuously and etoposide&#xD;
           phosphate IV continuously on days -7 to -4 and melphalan IV on days -7 to -5. PBSC and&#xD;
           GM-CSF are administered as in the first PBSCT.&#xD;
&#xD;
      Beginning no earlier than day 28 after the second PBSCT, patients undergo local radiotherapy&#xD;
      to the primary site and sites that are positive by meta-iodobenzylguanidine scan after&#xD;
      induction twice a day for 7 days (or once a day for 12 days if twice daily dosing is not&#xD;
      possible). Beginning on day 90 after the second PBSCT, patients receive oral isotretinoin&#xD;
      twice a day for 2 weeks. Treatment repeats every 4 weeks for 6 courses in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 31-39 patients will be accrued for this study within 22 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant-related mortality</measure>
    <description>The endpoint used for early stopping rule 9.51 will be transplant-related mortality (TRM). A TRM is defined as any death occurring within 30 days after either the first or second HDC/SCR. The acceptable TRM rate is 7.5%. This rate is based on TRM rates previously observed in the prior CCG study 594, CCG study 3891, and POG study 9640 of 7%, 6%, and 0%, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of symptomatic CMV, disseminated adenovirus infection, or EBV-LPD</measure>
    <description>The endpoint to be used in assessing early stopping rule 9.52 will be the incidence of symptomatic CMV, disseminated adenovirus infection, or EBV-LPD. Patients with positive CMV antigenemia or CMV urine culture only (without symptoms of CMV infection), or patients who have a positive culture for adenovirus without evidence of dissemination, or patients with a positive EBV PCR who do not exhibit significant clinical signs (such as adenopathy) or symptoms will not trigger the stopping rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of feasibility and toxicity at the end of the study is time to event. Time to event is defined as the time from registration on the study until the first of the following events occurs: relapse, progression, secondary malignancy, or death, including toxic death. If none of those events occurs, then the time of last contact with the patient is used. Time to event will be used to calculate the one-year Event-free Survival (EFS) rate.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>All Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotretinoin</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Newly diagnosed high-risk neuroblastoma&#xD;
&#xD;
               -  Histologically proven AND/OR&#xD;
&#xD;
               -  Bone marrow specimen showing clumps of tumor cells accompanied by elevated&#xD;
                  urinary catecholamines&#xD;
&#xD;
               -  Age 1-30:&#xD;
&#xD;
                    -  Must meet one of the following INSS staging criteria:&#xD;
&#xD;
                         -  Stage IV regardless of biologic factors&#xD;
&#xD;
                         -  Stage IIa/IIb with MYCN oncogene amplification (greater than 10) and&#xD;
                            unfavorable pathology&#xD;
&#xD;
                         -  Stage III with MYCN oncogene amplification (greater than 10) or&#xD;
                            unfavorable pathology&#xD;
&#xD;
                         -  Initially stage I, II, or IVS, that has progressed without interval&#xD;
                            chemotherapy&#xD;
&#xD;
               -  Under age 1:&#xD;
&#xD;
                    -  INSS stage III, IV, or IVS with MYCN amplification (greater than 10)&#xD;
&#xD;
          -  Must enter neuroblastoma biology study COG-ANBL00B1 within 2 weeks of diagnosis and&#xD;
             before entry on this study&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  30 and under at original diagnosis&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 1 prior course of chemotherapy on the intergroup low- or&#xD;
             intermediate-risk neuroblastoma studies prior to determination of MYCN status and&#xD;
             Shimada histology&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior emergent radiotherapy to sites of function- or life-threatening neuroblastoma&#xD;
             allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior systemic therapy for neuroblastoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan A. Grupp, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish RiteCampus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbia River Oncology Program</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Scott and White Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Marshfield Clinic Research Foundation</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Marcus KJ, Shamberger R, Litman H, von Allmen D, Grupp SA, Nancarrow CM, Goldwein J, Grier HE, Diller L. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol. 2003 Dec;25(12):934-40.</citation>
    <PMID>14663275</PMID>
  </reference>
  <reference>
    <citation>Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M, Geissler G, Marymount MH, Liu D, Kalapurakal JA, Shore RM, Bardo DM, Schmoldt J, Rademaker AW, Cohn SL. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol. 2002 May 1;20(9):2284-92.</citation>
    <PMID>11980999</PMID>
  </reference>
  <reference>
    <citation>Donovan J, Temel J, Zuckerman A, Gribben J, Fang J, Pierson G, Ross A, Diller L, Grupp SA. CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies. Med Pediatr Oncol. 2000 Dec;35(6):677-82.</citation>
    <PMID>11107145</PMID>
  </reference>
  <reference>
    <citation>Grupp SA, Stern JW, Bunin N, Nancarrow C, Adams R, Gorlin JB, Griffin G, Diller L. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Med Pediatr Oncol. 2000 Dec;35(6):696-700.</citation>
    <PMID>11107149</PMID>
  </reference>
  <reference>
    <citation>Grupp SA, Stern JW, Bunin N, Nancarrow C, Ross AA, Mogul M, Adams R, Grier HE, Gorlin JB, Shamberger R, Marcus K, Neuberg D, Weinstein HJ, Diller L. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol. 2000 Jul;18(13):2567-75.</citation>
    <PMID>10893288</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>October 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2003</study_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

